Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and RNA-Binding Protein (RBP) Target Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PCBP4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PCBP4 Recombinant Protein (KH Domains / Full Length) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View PCBP4 Products |
| Gene Delivery | PCBP4 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression studies. |
View PCBP4 Products |
| Benchmark Ab | Anti-PCBP4 Recombinant Antibody Recombinant positive control for Western Blot, IHC, and IP. |
View PCBP4 Products |
| Validator | PCBP4 siRNA Set For target knockdown and functional validation assays. |
View PCBP4 Products |
| Related Target A | PCBP1 Subfamily paralog; critical for selectivity and off-target screening. |
View PCBP1 Products |
| Related Target B | PCBP2 Subfamily paralog; high homology in KH domains; essential for counter-screening. |
View PCBP2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily counter-screening (PCBP1/2/3/4) | High-purity recombinant PCBP1, PCBP2, and PCBP4 proteins strictly verified by mass spectrometry. |
| RNA-binding pocket target engagement | Sequence-verified KH domain truncations ensuring structural integrity for biophysical assays. |
| Lack of Controls | Clinical benchmark-grade recombinant antibodies included for assay standardization. |
| False Positives in Phenotypic Screens | Sequence-specific siRNA pools included for precise target gene knockdown verification. |
Live PCBP4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PCBP4 therapeutics is intensifying, with major players shifting focus from traditional oncology targets to RNA-Binding Proteins (RBPs). PCBP4 (Poly(rC)-binding protein 4) acts as a critical post-transcriptional regulator of mRNA stability and translation, particularly in p53-mediated apoptotic pathways and cell cycle checkpoints. As first-generation RBP inhibitors reach the clinic, the next wave of R&D is targeting highly selective small molecules and PROTACs designed to disrupt PCBP4-RNA interactions or induce targeted degradation in refractory solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (RBP Inhibitor) | Biotech Startups, Academic Consortia | Lung Cancer, Breast Cancer | Biophysical Binding Assays (Need high-purity, sequence-verified PCBP4 protein) |
| PROTAC (Degrader) | Targeted Protein Degradation Pioneers | Ovarian Cancer, Refractory Tumors | Ubiquitination & Ternary Complex Assays (Need functional KH-domain fragments) |
| RNAi / Antisense | Oligonucleotide Therapeutics Developers | Oncology, Fibrotic Diseases | In vitro knockdown validation (Need validated siRNA and Lentivirus systems) |